Regranex Market Report 2026

Regranex Market Overview

• The Regranex market growth in the historic period has been driven by increasing prevalence of diabetic foot ulcers, rising incidence of chronic non-healing wounds • Market expansion is supported by increasing diabetic population globally, rising demand for personalized wound care treatments • Growth Driver: Rising Diabetes Prevalence To Drive Growth In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Regranex Market?

Regranex is a topical medication containing becaplermin, a recombinant form of platelet-derived growth factor (PDGF). It is used to promote healing of diabetic foot ulcers by stimulating tissue regeneration and blood vessel growth. The main types of indications in regranex are diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Diabetic foot ulcers (DFUs) are sores on the feet caused by nerve damage and poor circulation in people with diabetes, leading to potential infections and amputations if untreated. The several formulations involved are topical gel, ointment, and combination therapies. It is distributed through various channels such as direct sales, wholesalers, retail pharmacies, and online pharmacies, catering to various end users such as pediatric, adult, and geriatric.

What Is The Regranex Market Growth Forecast?

The growth in the forecast period can be attributed to increasing diabetic population globally, rising demand for personalized wound care treatments, expansion of outpatient wound care centers, growing investment in regenerative medicine, development of next-generation biologic formulations. Major trends in the forecast period include increasing use of recombinant growth factor therapies, rising focus on advanced wound care solutions, growing adoption of targeted topical biologics, expansion of combination wound healing therapies, enhanced emphasis on chronic ulcer management.

What Are The Drivers Of The Regranex Market?

Rising prevalence of diabetes is expected to propel growth of the regranex market going forward. Diabetes is a group of diseases that affect how the body processes blood sugar, with the most common types being Type 1, where the body doesn't produce insulin, and Type 2, where the body becomes resistant to insulin or doesn't produce enough. The rising prevalence of diabetes can be attributed to factors such as unhealthy diets, sedentary lifestyles, obesity, genetic predisposition, aging populations, and increased urbanization. Regranex helps reduce complications in diabetes by promoting the healing of diabetic foot ulcers, thereby preventing severe outcomes like amputations. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes drives the growth of the regranex industry. The growth in healthcare infrastructure is expected to propel growth of the regranex market going forward. Healthcare infrastructure refers to the physical and organizational systems, including facilities, equipment, health IT, and essential utilities, that enable the effective delivery of healthcare services. The growth in healthcare infrastructure can be attributed to factors such as increasing healthcare demand, technological advancements, government and private sector investments, urbanization, pandemic preparedness, healthcare policy reforms, and rising healthcare expenditures. Regranex enhances healthcare infrastructure by promoting faster wound healing, reducing hospitalizations, and improving patient outcomes, thus driving cost efficiency. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the growth in healthcare infrastructure drives the growth of the regranex industry.

Key Players In The Global Regranex Market

Major companies operating in the regranex market are Smith And Nephew plc

What Are Latest Mergers And Acquisitions In The Regranex Market?

In March 2025, Lynch Regenerative Medicine, LLC, a U.S.-based regenerative medicine company, acquired exclusive rights to REGRANEX gel and recombinant purified platelet derived growth factor (PDGF) from Smith & Nephew, Inc., for an undisclosed amount. With this acquisition, Lynch Regenerative Medicine aims to reposition REGRANEX beyond its traditional diabetic foot ulcer indication into broader soft tissue regeneration and aesthetic wound healing markets, leveraging its expertise in pure PDGF development. Smith & Nephew, Inc., is a U.K.-based medical technology firm providing advanced wound care products, orthopedics, and surgical systems.

What Defines the Regranex Market?

The regranex market consists of sales of products including dermagraft, oasis wound matrix, strataGraft, apligraf, and acticoat. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Regranex Market Report 2026?

The regranex market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the regranex industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.